Vigilant and Biotech-IgG sign deal to market OncAlert oral cancer risk assessment system

11 March 2015 (Last Updated March 11th, 2015 18:30)

US-based Vigilant Biosciences has entered a three-year exclusive sales and marketing agreement with Sweden-based Biotech-IgG for the distribution of the OncAlert Oral Cancer Risk Assessment system in Denmark, Norway and Sweden.

US-based Vigilant Biosciences has entered a three-year exclusive sales and marketing agreement with Sweden-based Biotech-IgG for the distribution of the OncAlert Oral Cancer Risk Assessment system in Denmark, Norway and Sweden.

The system includes a rapid, point-of-care risk assessment test called OncAlert POC Test and a quantitative, laboratory test OncAlert LAB Assay.

As part of the deal, Biotech-IgG will exclusively market and sell OncAlert POC Test and OncAlert LAB Assay to dental and oncology markets in Scandinavia, in pursuit of CE Mark registration approvals of the products, which are expected to be secured in the second quarter of 2015.

Biotech-IgG supplies products for medical diagnostics and research, routine and process applications for the life science industry.

"The system includes a rapid, point-of-care risk assessment test called OncAlert POC Test and a quantitative, laboratory test OncAlert LAB Assay."

Vigilant Biosciences founder Matthew Kim said: "Our agreement with Biotech-IgG for the sale of our OncAlert system in Scandinavia represents our first European Union market partner, and is a significant step for Vigilant as we prepare to launch our oral cancer risk assessment system globally through strategic commercialisation partnerships.

"Hundreds of thousands of people continue to suffer from this disease each year, and many are diagnosed when the cancer is already at a late stage.

"Our mission is to work with our worldwide partners, such as Biotech-IgG, to enhance the lives of patients by providing products that enable earlier detection and intervention."

The company's OncAlert Oral Cancer Risk Assessment system is based on patented technology that detects specific protein markers known to indicate an elevated risk for oral cancer, even prior to observation of visual or physical symptoms.

The company said the test can be applied to every adult, with particular emphasis on high-risk populations such as current and former tobacco users, those who consume alcohol and people with human papillomavirus (HPV).

Both the rapid point-of-care test and lab assay that include the OncAlert Oral Cancer Risk Assessment system are currently under the CE Mark registration approval process, and are expected for release in the second quarter of 2015.